Harvard Bioscience (FRA:HBI0) Total Receivables: €12.59 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:HBI0 Harvard Bioscience Inc FRA:HBI0
53 GF Score
Price €4.08
GF Value €6.70
! 9 Warning Signs
View Full Analysis

What is Harvard Bioscience Total Receivables?

Harvard Bioscience FRA:HBI0 53 Total Receivables is €12.59 Mil as of Jun. 2026. GuruFocus rates FRA:HBI0 with a GF Score™ of 53/100 and a GF Value™ of €6.70. The stock has 9 warning signs investors should review.

Harvard Bioscience's Total Receivables for the quarter that ended in Jun. 2026 was €12.59 Mil.

Harvard Bioscience Total Receivables Related Terms

Harvard Bioscience Total Receivables Historical Data

* Premium members only.

The historical data trend for Harvard Bioscience's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harvard Bioscience Total Receivables Chart

Harvard Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.32 15.77 14.76 14.20 13.70

Harvard Bioscience Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.35 10.32 13.70 12.61 12.59
FRA:HBI0
53GF Score
Harvard Bioscience Inc FRA:HBI0
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Harvard Bioscience Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €12.59 Mil mean?
Harvard Bioscience (FRA:HBI0) has a Total Receivables of €12.59 Mil as of Jun. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Harvard Bioscience and its competitors.
Is Harvard Bioscience's Total Receivables too high?
Harvard Bioscience's current Total Receivables is €12.59 Mil. Overall, Harvard Bioscience has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Harvard Bioscience's Total Receivables compare to RVP and MLSS?
Harvard Bioscience's Total Receivables of €12.59 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Medical Devices & Instruments company?
A good Total Receivables depends on the Medical Devices & Instruments industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Harvard Bioscience and its competitors. Harvard Bioscience's current Total Receivables is €12.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Bioscience stock overvalued right now?
Harvard Bioscience (FRA:HBI0) has a current Total Receivables of €12.59 Mil. The stock's GF Value™ is €6.70, compared to a current price of €4.08 — trading 39.1% below its estimated fair value. The current Total Receivables is €12.59 Mil. Harvard Bioscience's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Harvard Bioscience (FRA:HBI0), the current Total Receivables is €12.59 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harvard Bioscience (FRA:HBI0) Overvalued in 2026?

Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued. The current stock price of €4.08 is trading 39.1% below its estimated GF Value™ of €6.70.

Key valuation signals for FRA:HBI0:

  • Total Receivables: €12.59 Mil
  • GF Value™: €6.70 vs. price of €4.08 (39.1% below fair value)
  • GF Score™: 53/100 with 9 warning signs

No single metric tells the full story. See the FRA:HBI0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Harvard Bioscience Business Description

Other Exchanges HBIO:USA
Address 84 October Hill Road, Suite 10, Holliston, MA, USA, 01746
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
53GF Score

Get the complete analysis for FRA:HBI0

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.08
Price
€6.70
GF Value